FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894238189> ?p ?o ?g. }

• W2894238189 endingPage "586" @default.
• W2894238189 startingPage "576" @default.
• W2894238189 abstract "Mutations in genes of the RAS-BRAF-MAPK-ERK pathway have not been fully explored in patients with chronic lymphocytic leukemia. We, therefore, analyzed the clinical and biological characteristics of chronic lymphocytic leukemia patients with mutations in this pathway and investigated the in vitro response of primary cells to BRAF and ERK inhibitors. Putative damaging mutations were found in 25 of 452 patients (5.5%). Among these, BRAF was mutated in nine patients (2.0%), genes upstream of BRAF (KITLG, KIT, PTPN11, GNB1, KRAS and NRAS) were mutated in 12 patients (2.6%), and genes downstream of BRAF (MAPK2K1, MAPK2K2, and MAPK1) were mutated in five patients (1.1%). The most frequent mutations were missense, subclonal and mutually exclusive. Patients with these mutations more frequently had increased lactate dehydrogenase levels, high expression of ZAP-70, CD49d, CD38, trisomy 12 and unmutated immunoglobulin heavy-chain variable region genes and had a worse 5-year time to first treatment (hazard ratio 1.8, P=0.025). Gene expression analysis showed upregulation of genes of the MAPK pathway in the group carrying RAS-BRAF-MAPK-ERK pathway mutations. The BRAF inhibitors vemurafenib and dabrafenib were not able to inhibit phosphorylation of ERK, the downstream effector of the pathway, in primary cells. In contrast, ulixertinib, a pan-ERK inhibitor, decreased phospho-ERK levels. In conclusion, although larger series of patients are needed to corroborate these findings, our results suggest that the RAS-BRAF-MAPK-ERK pathway is one of the core cellular processes affected by novel mutations in chronic lymphocytic leukemia, is associated with adverse clinical features and could be pharmacologically inhibited." @default.
• W2894238189 created "2018-10-05" @default.
• W2894238189 creator A5000725252 @default.
• W2894238189 creator A5003059028 @default.
• W2894238189 creator A5007109257 @default.
• W2894238189 creator A5007142149 @default.
• W2894238189 creator A5007551486 @default.
• W2894238189 creator A5008209878 @default.
• W2894238189 creator A5010733763 @default.
• W2894238189 creator A5020702876 @default.
• W2894238189 creator A5024516606 @default.
• W2894238189 creator A5029161067 @default.
• W2894238189 creator A5033486428 @default.
• W2894238189 creator A5046656441 @default.
• W2894238189 creator A5050933998 @default.
• W2894238189 creator A5052695708 @default.
• W2894238189 creator A5054614889 @default.
• W2894238189 creator A5059323129 @default.
• W2894238189 creator A5061167008 @default.
• W2894238189 creator A5063490459 @default.
• W2894238189 creator A5065232101 @default.
• W2894238189 creator A5071261900 @default.
• W2894238189 creator A5076803852 @default.
• W2894238189 creator A5077832916 @default.
• W2894238189 creator A5078732174 @default.
• W2894238189 creator A5087974982 @default.
• W2894238189 creator A5088963827 @default.
• W2894238189 creator A5091420701 @default.
• W2894238189 date "2018-09-27" @default.
• W2894238189 modified "2023-10-18" @default.
• W2894238189 title "Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia" @default.
• W2894238189 cites W1490956705 @default.
• W2894238189 cites W1966165090 @default.
• W2894238189 cites W1973388908 @default.
• W2894238189 cites W1988436508 @default.
• W2894238189 cites W1988785346 @default.
• W2894238189 cites W1999233413 @default.
• W2894238189 cites W2031121711 @default.
• W2894238189 cites W2040760628 @default.
• W2894238189 cites W2054946171 @default.
• W2894238189 cites W2069682021 @default.
• W2894238189 cites W2080719056 @default.
• W2894238189 cites W2084952484 @default.
• W2894238189 cites W2087370251 @default.
• W2894238189 cites W2088580309 @default.
• W2894238189 cites W2093884670 @default.
• W2894238189 cites W2099780734 @default.
• W2894238189 cites W2102036352 @default.
• W2894238189 cites W2105660237 @default.
• W2894238189 cites W2109592760 @default.
• W2894238189 cites W2113895281 @default.
• W2894238189 cites W2124662474 @default.
• W2894238189 cites W2124920464 @default.
• W2894238189 cites W2128542677 @default.
• W2894238189 cites W2130375238 @default.
• W2894238189 cites W2132630169 @default.
• W2894238189 cites W2136272158 @default.
• W2894238189 cites W2145842706 @default.
• W2894238189 cites W2148576269 @default.
• W2894238189 cites W2149926719 @default.
• W2894238189 cites W2163188200 @default.
• W2894238189 cites W2178192018 @default.
• W2894238189 cites W2221645419 @default.
• W2894238189 cites W2280983302 @default.
• W2894238189 cites W2297081735 @default.
• W2894238189 cites W2310716991 @default.
• W2894238189 cites W2333328526 @default.
• W2894238189 cites W2335844855 @default.
• W2894238189 cites W2343910676 @default.
• W2894238189 cites W2410865989 @default.
• W2894238189 cites W2558715006 @default.
• W2894238189 cites W2589333438 @default.
• W2894238189 cites W2589933859 @default.
• W2894238189 cites W2616987580 @default.
• W2894238189 cites W2755066803 @default.
• W2894238189 cites W2769423933 @default.
• W2894238189 cites W2774483419 @default.
• W2894238189 cites W4210508051 @default.
• W2894238189 cites W4244151789 @default.
• W2894238189 doi "https://doi.org/10.3324/haematol.2018.196931" @default.
• W2894238189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6395334" @default.
• W2894238189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262568" @default.
• W2894238189 hasPublicationYear "2018" @default.
• W2894238189 type Work @default.
• W2894238189 sameAs 2894238189 @default.
• W2894238189 citedByCount "37" @default.
• W2894238189 countsByYear W28942381892019 @default.
• W2894238189 countsByYear W28942381892020 @default.
• W2894238189 countsByYear W28942381892021 @default.
• W2894238189 countsByYear W28942381892022 @default.
• W2894238189 countsByYear W28942381892023 @default.
• W2894238189 crossrefType "journal-article" @default.
• W2894238189 hasAuthorship W2894238189A5000725252 @default.
• W2894238189 hasAuthorship W2894238189A5003059028 @default.
• W2894238189 hasAuthorship W2894238189A5007109257 @default.
• W2894238189 hasAuthorship W2894238189A5007142149 @default.
• W2894238189 hasAuthorship W2894238189A5007551486 @default.
• W2894238189 hasAuthorship W2894238189A5008209878 @default.

• next